Newron Pharmaceuticals SpA (NWRN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 8.680 |
|---|---|
| 52-week range | 5.720 – 31.850 |
| Return, 1 month / 3 months | −21.5% / −28.3% |
| Return, 1 year / 3 years | −38.8% / +82.0% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 60.5% |
| Worst drawdown (1 year) | -76.3% |
| Average daily value traded | 0.72M CHF |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Newron Pharmaceuticals is a biopharmaceutical company based in Italy that focuses on treatments for disorders of the central nervous system. Its main product is safinamide, a medicine for Parkinson's disease developed with a partner and marketed in several countries. The company also works on experimental compounds for neurological and psychiatric conditions, including treatments for pain and for symptoms associated with schizophrenia. Its customers are mainly pharmaceutical partners and healthcare systems that distribute its medicines.
On this site Newron Pharmaceuticals SpA appears as a stock on the SIX Swiss Exchange (Switzerland), code NWRN, with prices in Swiss francs (CHF). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Newron Pharmaceuticals SpA (NWRN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 8.680 on 22 October 2026.
Its price-based Market X-Ray is 11 out of 100 (a weak price profile), ranking 214 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 38.8% and over the last three months it fell 28.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 2 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -39.5% | ||
| From 52-week high | -71.4% | ||
| Momentum | 6 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -28.3% | ||
| 6-month return | -47.1% | ||
| 12-month return, skipping the last month | -22.0% | ||
| Stability (higher is calmer) | 7 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -76.3% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.72M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.0% |
|---|---|
| 1 month | −21.5% |
| 3 months | −28.3% |
| 6 months | −47.1% |
| 1 year | −38.8% |
| 3 years | +82.0% |
| 5 years | +355.9% |
Signals
| 50-day / 200-day average | 10.368 / 14.348 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.598 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.